

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : John Eldridge *et al.*
Application No. : 10/550,313 Confirmation No.: 8349
Filed : June 30, 2006
Examiner : Kelaginamane T. Hiriyanne
Group Art Unit : 1633
For : IMMUNOGENIC COMPOSITION AND METHODS

Mail Stop RCE

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

New York, New York
August 3, 2010

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants hereby make the following documents of record in the above-identified patent application: *

U.S. PATENT DOCUMENTS

<u>Patent No.</u>	<u>Issue Date</u>	<u>Patentee(s)</u>
4,710,463	12-01-1987	Murray
5,589,466	12-31-1996	Felgner et al.
5,593,972	01-14-1997	Weiner et al.

* A completed Form PTO/SB/08A/B listing these documents is attached hereto.

NON-PATENT LITERATURE DOCUMENTS

ALLEN et al., "Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication," *Journal of Virology*, 76(8):4108-4112 (2002).

BROCKMAN et al., "Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity," *Journal of Virology*, 76(8):3678-3687 (2002).

CLEMENTS-MANN et al., "Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1_{MN} gp120, HIV-1_{SF2} recombinant gp120, or both vaccines in seronegative adults," *The Journal of Infectious Disease*, 177(5):1230-1246 (1998)

DAEMEN et al., "Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7," *Gene Therapy*, 9(2):85-94 (2002).

EVANS et al., "Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the *Salmonella* type III secretion antigen delivery system," *Journal of Virology*, 77(4):2400-2409 (2003).

GILBERT et al., "Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in *Lactococcus lactis*," *Infection and Immunity*, 68(6):3251-3260 (2000).

HANKE et al., "Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine," *Journal of General Virology*, 84(Pt 2):361-368 (2003).

HARRINGTON et al., "Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles," *Journal of Virology*, 76(2):730-742 (2002).

HÉCHARD et al., "Proteic boost enhances humoral response induced by DNA vaccination with the *dnaK* gene of *Chlamydia abortus* but fails to protect pregnant mice against a virulence challenge," *Vet Res.*, 34(1):119-125 (2003).

HERMONAT et al., "Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells," *Proc. Natl. Acad. Sci.*, 81(20):6466-6470 (1984).

HORTON et al., "Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral

replication but does not prevent disease progression following challenge with pathogenic SIVmac239," *Journal of Virology*, 76(14):7187-7202 (2002).

LEE et al., "Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system," *Journal of Virology*, 76(4):1649-1662 (2002).

LOEHR et al., "Priming by DNA immunization augments T-cell responses induced by modified live bovine herpesvirus vaccine," *Journal of General Virology*, 82(Pt 12):3035-3043 (2001).

McDERMOTT et al., "Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques," *Journal of Virology*, 79(24):15556-15566 (2005).

PANG et al., "Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV," *BMC Microbiology*, 1:28,1-9 (2001).

QIAN et al., "Construction of a *tetR*-integrated *Salmonella enterica* serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of *Plasmodium falciparum* for applications in human Vaccine production," *Infection and Immunity*, 70(4):2029-2038 (2002).

VINNER et al., "Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost," *Journal of General Virology*, 84(Pt 1):203-213 (2003).

WOODBERRY et al., "Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias," *The Journal of Immunology*, 170(5):2599-2604 (2003).

XIANG et al., "Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product," *Journal of Virology*, 76(6):2667-2675 (2002).

REMARKS

In accordance with 37 C.F.R. § 1.98(a)(2), applicants submit herewith copies of non-patent literature documents. No copies of the listed U.S. patent documents are being submitted. 37 C.F.R. § 1.98(a)(2)(ii).

Applicants respectfully request that these documents be (1) considered by the Examiner prior to issuance of any patent from this application; and (2) printed on any patent that may issue from this application. Applicants also request that a copy of enclosed Form PTO/SB/08A/B, as considered and initialled by the Examiner, be returned with the next communication.

This supplemental IDS is being filed concurrently with a Request for Continued Examination. Accordingly, pursuant to 37 C.F.R. § 1.97(b)(4), submission of this Supplemental IDS requires no fees. However, if for any reason, a fee is due, the Director is hereby authorized payment of the fee to Deposit Account No. 06-1075, under Order No. PCFC-439-101.

Respectfully submitted,

/Jane T. Gunnison/

Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
Customer No. 01473

ROPES & GRAY LLP
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax: (617) 235-9492